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ABSTRACT* 
Warfarin therapy is underused in the target at-risk 
elderly population. Clinicians perceive that older 
patients are reluctant to use this therapy, however 
the perspective of patients or their carers has yet to 
be explored.  
Objective: To explore in-depth the perspectives of 
elderly patients and/or their carers regarding the 
use of warfarin therapy.  
Method: A qualitative study, using semi-structured 
group interviews was undertaken. The audio-taped 
discussions were transcribed verbatim, then 
thematically analysed to identify emergent themes. 
Group discussions were conducted at a major 
Sydney teaching hospital, over a 2-month period. 
Individuals aged 65 years or older (and/or their 
carers) who were using long-term (6 months) 
warfarin therapy were recruited by voluntary 
response to study flyers. 
Results: 17 patients and carers (mean age 77.2 
SD=7.5 years) participated in one of two focus 
groups. Five core themes emerged regarding 
warfarin therapy: inadequate knowledge and 
understanding about it, patients/carers variable 
experience of information provision, cycle of 
reactions to being on it, issues in its practical 
management, and the spectrum of experiences with 
it. Overall, participants were very accepting of the 
therapy, describing a high level of compliance, 
despite initial fears and anxieties, and a relative lack 
of knowledge. Patients felt somewhat abandoned in 
their management of warfarin due to the lack of 
ongoing support services in the community, and 
inadequate information provision. 
Conclusions: Elderly patients and their carers 
appear to be quite accepting of warfarin therapy, in 
contrast to the perceptions of health care 
professionals. More effort is needed, however, in 
                                            
*Beata V. BAJOREK. BPharm , DipHPharm, PhD. Lecturer 
in Pharmacy. Research Associate, Clinical Pharmacology 
and Aged Care & Rehabilitation, Royal North Shore 
Hospital. Faculty of Pharmacy,  
University of Sydney (Australia). 
Susan J. OGLE. MBBS, FRACP. Clinical Senior Lecturer 
in Medicine. Head Aged Care & Rehabilitation Medicine. 
Department of Aged Care and Rehabilitation, Royal North 
Shore Hospital. St Leonards (Australia) 
Margaret J. DUGUID. BPharm. Former Head Department 
of Pharmacy, Royal North Shore Hospital. St Leonards 
(Australia). 
Gillian M. SHENFIELD. DM, FRCP, FRACP. Former Head 
Department of Clinical Pharmacology. Royal North Shore 
Hospital. St Leonards (Australia). 
Ines KRASS. BPharm, DipHPharm, PhD. Head of 
Department, Pharmacy Practice, Faculty of Pharmacy, 
University of Sydney (Australia). 
terms of information provision, particularly in the 
form of community-based services, to assist 
patients in the long-term management of warfarin.   
 
Keywords: Warfarin. Attitude to Health. Aged. 
Qualitative Research. Australia.  
 
 
SOPESANDO RIESGO Y BENEFICIO: 
PERSPECTIVA DEL PACIENTE ANCIANO A 
TRATAMIENTO CON WARFARINA 
 
RESUMEN 
El tratamiento con warfarina se sub-utiliza en los 
ancianos de alto riesgo.   Los clínicos perciben que 
los ancianos son reacios a este tratamiento, sin 
embargo la perspectiva de los pacientes y de sus 
cuidadores aún no ha sido estudiada. 
Objetivo: Explorar en profundidad las perspectivas 
de los pacientes ancianos y/0 sus cuidadores sobre 
el uso de tratamiento con warfarina. 
Método: Se realizó un estudio cualitativo, 
utilizando entrevista semi-estructurada en grupos. 
Las discusiones grabadas se transcribieron a papel, 
y se analizaron temáticamente para identificar los 
temas emergentes. Las discusiones en grupos se 
realizaron en un gran hospital universitario de 
Sydney durante un periodo de dos meses. Mediante 
respuesta voluntaria a folletos, se reclutó a 
individuos de 65 o más años (y/0 sus cuidadores) 
que estaban utilizando crónicamente (6 o más 
meses) tratamiento con warfarina. 
Resultados: 17 pacientes y cuidadores (edad media 
77,2 DE=7,5 años) participaron en uno de los dos 
grupos focales. Emergieron 5 temas principales en 
lrelación al tratamiento con warfarina: 
conocimiento y entendimiento inadecuado, 
experiencia variable de pacientes/cuidadores de la 
información proporcionada, ciclo de reacciones de 
estar bajo esto, problemas de manejo práctico, y 
espectro de experiencias con el tratamiento. 
Generalmente los participantes aceptaban bien el 
tratamiento, describiendo altos niveles de 
cumplimiento, a pesar de sus miedos y ansiedades 
inicial, y la relativa falta de conocimiento. Los 
pacientes se sentían algo abandonados en su 
manejo del tratamiento con warfarina debido a la 
falta de servicios de apoyo continuo en la 
comunidad y de la inadecuada provisión de 
información. 
Conclusión: Los pacientes ancianos y sus 
cuidadores parecen estar tranquilos aceptando el 
tratamiento con warfarina, en contraste con la 
percepción de los profesionales de la salud. Sin 
embargo se necesita un mayor esfuerzo en relación 
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a la provisión de información, especialmente en los 
servicios comunitarios, para ayudar a los pacientes 
en el manejo de la warfarina a largo plazo. 
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INTRODUCTION 
Although a potentially life-saving medication, 
warfarin is difficult to manage for patients and health 
professionals alike. This anticoagulant carries an 
inherent risk of excessive, and potentially life-
threatening, bleeding that is amplified by its 
complex pharmacology, as well as drug and food 
interactions. Hence, there is a very narrow range of 
dosages within which warfarin carries a low risk of 
bleeding, but is also effective in preventing clots and 
strokes. Achieving the optimal dose for each patient 
requires vigilance on both the part of the patient and 
the health carer, and involves regular blood testing 
to measure clotting time (INR, international 
normalised ratio), frequent dosage adjustment and 
careful titration, and extensive patient education. 
In view of these difficulties, clinicians have been 
reluctant to prescribe warfarin, to the extent that it 
remains underutilised in high-risk patients, e.g., 
those with the common cardiac arrhythmia, atrial 
fibrillation1-5, particularly the target elderly 
population.6 One key reason cited by clinicians for 
this suboptimal use is the perceived refusal of 
patients’ to use, and therefore be compliant with, 
this complicated and potentially risky therapy.7-10 
However, this notion has neither been explored nor 
confirmed with patients, and is in contrast to the 
findings reported in patient surveys.9-12  
Therefore, the aim of this study was to explore in-
depth the issues surrounding the long-term use of 
warfarin from the perspective of elderly patients 
and/or their carers. The specific objectives were to: 
describe patients’ and/or carers’ experiences and 
attitudes toward the use of warfarin; explore their 
perceptions regarding the risks and benefits of 
warfarin therapy; identify any ‘barriers’ to the long-
term use of warfarin as perceived and/or 
experienced by them; and investigate their 
perceived roles regarding warfarin therapy. 
 
METHODS  
Study Design 
This qualitative study was undertaken at a major 
Sydney teaching hospital, over a 2-month period. 
Group interviews (focus groups) were conducted to 
draw upon the attitudes, feelings, beliefs, 
experiences and reactions of the participants in a 
way that would not be feasible using observation, 
one-to-one interviewing, or questionnaire surveys 
alone.13 A semi-structured process was used, where 
each discussion was moderated by a ‘facilitator’, co-
facilitator, and scribe using a set of broad open-
ended questions that reflected the pre-determined 
research objectives. Specific topics that were 
explored included: participants’ understanding of, 
experiences with, and management of warfarin 
therapy; specific barriers to using warfarin therapy; 
and overall, how participants felt about being on 
warfarin therapy. Based on our theoretical 
framework (described below), sub-sets of probing 
questions were designed to explore issues within 
the discussion topics, which enabled the facilitator 
to promote discussion and elicit detailed responses; 
all questions were pre-tested in mock individual 
interviews with non-participants. Demographic data 
were collected prior to the group interviews using a 
specially designed questionnaire. Approval for the 
conduct of the study was granted by the institutional 
Human Research and Ethics Committee. 
Theoretical framework 
A conceptual model of potential issues, including 
biological, psychological and social aspects, 
surrounding warfarin use was developed (Figure 1). 
This was analogous to that described by an 
Australian study examining the biopsychosocial 
impact of a disease and its treatment on patients 
and their families.14 
Recruitment of Participants 
Individuals were eligible to participate in this study if 
they were either: 1) elderly (equal or over 65 years 
old) and were prescribed long-term (equal or over 6 
months) warfarin therapy for a chronic condition 
such as atrial fibrillation, or 2) were the primary 
carer of such a patient. Recruitment of participants 
was by voluntary response to study flyers displayed 
in key locations around both the project hospital and 
larger community within the Northern Sydney Area 
Health Service, e.g., aged care, cardiology, general 
medicine, and neurology wards; outpatient clinics; 
pathology collection areas; and local community 
centres that provided medicine information sessions 
for senior citizens. Additionally, project flyers were 
mailed to patients who had previously expressed an 
interest, to the investigators, in sharing their 
opinions about warfarin use. Sampling was 
therefore largely opportunistic to capture the target 
population, and purposive to find patients and/or 
carers willing to discuss their experiences. 
Participants provided their informed written consent 
to participate after reading the approved project 
information sheet, as approved by the institutional 
human research and ethics committee. To 
compensate for any losses incurred by attendance 
all participants were offered a nominal payment of 
AUD 25.00, reimbursement of travel expenses, and 
the provision of food and beverages. Information 
regarding this payment was provided upon enquiry 
during the recruitment stage, and was declared on 
the consent forms. 
Data collection and analysis 
Since data collection was dependant on the verbal 
responses of participants, each session was audio-
taped. In addition, the scribe also observed and 
noted any non-verbal behaviour (e.g., facial 
expressions, body language, paralanguage etc) that 
reinforced any significant statements made by 
participants.  
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Figure 1. Conceptual model of the various biopsychosocial* factors affecting the use of warfarin (adapted 
from White and Grenyer, 1999.) 
 
Once the audio-taped discussions were transcribed 
verbatim, they were content-analysed to identify 
emergent themes. A phenomenological approach 
was used in this study, focussing on understanding 
the essence of experiences about a phenomenon 
via statements, meanings, themes, and general 
descriptions of the experience.15,16 
Several measures were taken to ensure that the 
conclusions drawn from the analysis were valid, i.e., 
that they were consistent with the actual content 
such that the findings were grounded in data, 
inferences were logical, and thematic structures 
were legitimate. First, two of the investigators 
(acting as co-facilitator and scribe) observed the 
discussions.17 Second, these two investigators 
independently read through the transcripts and 
identified relevant themes, issues and supporting 
statements, before jointly discussing the findings to 
attain a consensus. Third, the findings were 
checked against the supplementary notes taken by 
the scribe. Fourth, the findings were reviewed by 
the main facilitator, as well as fed-back to some of 
the participants to ensure the accuracy of the 
session’s interpretation. 
 
RESULTS  
Participants 
In total, 17 individuals (14 patients and 3 carers) 
took part in one of two, 1-hour long, focus groups. 
On average, participants were 77.2 (+/- 7.5) years 
old (range: 65 - 91 years). The mean length of time 
that these participants were using (i.e., taking or 
administering) warfarin therapy was 6.35 years 
(range: 0.5 - 29 years).  In all cases, warfarin 
therapy was prescribed for stroke prevention in 
atrial fibrillation; in one individual there was an 
additional indication for warfarin (artificial heart 
valves). 
Emergent themes 
Similar themes were identified between the two 
patient/carer groups, and hence the data were 
pooled. Overall, five core themes emerged: 
1. Inadequate knowledge and understanding of 
warfarin therapy 
2. Patients/Carers experience of information 
provision  
3. Patient/Carer reactions to being on warfarin 
4. Self-management of warfarin therapy 
5. Spectrum of experiences with warfarin 
Theme 1:Inadequate knowledge and understanding 
of warfarin therapy 
Participants expressed, both consciously and 
subconsciously (as implied through their 
descriptions), a lack of understanding about 
warfarin, both in terms of general concepts and 
specific aspects of the therapy (Table 1). It was not 
explicitly understood that it was a long-term 
preventative therapy against stroke and other 
‘blood-clots’ arising from the altered heart rhythm. 
However, participants knew that it was related to the 
overall treatment of atrial fibrillation, often 
associating it with the procedure of direct current 
cardioversion, whether successful or unsuccessful. 
A few believed that warfarin was an alternative to 
cardioversion, with some expressing a preference 
for either treatment. Many were also unable to 
relate the risk of stroke to their atrial fibrillation or 
other underlying condition. Only those taking 
warfarin for secondary stroke prevention knew its 
indication fully. 
I want to know what happens to you, will you 
have a stroke or whatever it is? What am I 
taking it for? Participant 1 
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Heart fibrillation and then the stroke comes 
next. Participant 2 
Oh I see. Well. Participant 1 
I was just told I had to take it to prevent blood 
clots! Participant 3 
As a consequence of the lack of understanding 
about warfarin’s purpose, there was also uncertainty 
about the duration of the therapy. 
No … [the doctor] said you are on it but he 
didn’t say whether you are coming off or 
whether you are going to stay on it! 
 
Table 1: Inadequate knowledge and understanding of warfarin therapy 
Regarding the indication …. 
Warfarin doesn’t stop the fibrillation as far as I am concerned. But, the alternative of having an electric shock as somebody 
mentioned which would maybe stabilise it and I said “no thanks”. 
 
Heart fibrillation. [Warfarin] - that’s the one I know. It thins the blood …  warfarin is a no-no … I would rather suffer the … 
shock and put you out and get the electric thing. 
 
I had a few mini- strokes before and [warfarin therapy] is try to avoid them. 
Regarding INR [blood tests] and dosing … 
I take 4mgs and it keeps [the INR level] about 2.7, [the doctor] doesn’t want to get it too high, it is not important because I 
keep very good health otherwise, you know, I have no blood pressure, those sort of problems. And if I take 5mgs the nose 
starts bleeding so I have to keep [the INR] to 2 or 3. 
 
I seem to have been on fairly high doses for a while … I am currently on 4 but I have been up as far as 6.  
 
We had a friend up at Gosford he was on 10 … and I didn’t think that was right. But that is what he said his doctor put him 
on - 10 mgs! 
Provision of conflicting information … 
Regarding alcohol … 
• But, aren’t you supposed to avoid alcohol? 
• No, well I have had my glass of red wine every day of my life since I was a child and they said whatever you do 
don’t stop it.  
 
REGARDING CONCOMITANT MEDICATION … 
• There was sticker on one of the medication boxes that said you shouldn’t take aspirin with this … but the 
specialist said you take half a Solprin  … so you get sort of a conflicting thing. 
 
Regarding dietary restrictions … 
It tells me mainly to avoid greens … a little bit of lettuce in a salad is all she ever has. 
 
A similar deficit in knowledge and understanding 
was expressed on the practical aspects of warfarin 
use. Most participants accepted that blood (INR) 
testing was a necessary and routine part of the 
therapy, however, they did not understand how it 
related to the risk of either bleeding or stroke. 
Although they broadly understood that the INR was 
somehow an indicator of the necessary warfarin 
dose the vast majority believed that high doses 
were reserved for ‘sicker’ patients and were a 
marker of poorer health, a concept applied to most 
other medications (but not relevant to warfarin). 
It became apparent that some of these 
misunderstandings originated from the conflicting 
advice received from either their peers (i.e., other 
patients, carers) or health professionals. Issues 
such as alcohol intake, diet, and concomitant use of 
other medication (especially aspirin), were most 
prone to being misconstrued. Participants firmly, but 
falsely, believed that they had to adhere to strict 
dietary restrictions, without reference to vitamin K 
intake or its relationship to the INR. 
Despite some obvious misunderstandings, it was 
clear that participants knew more about warfarin 
than any other concomitant medication that they 
were taking. On the subject of warfarin, they were 
able to give comprehensive accounts of their 
treatment regimens and particular recording 
systems. 
Theme 2: Patients experience of information 
provision 
Whilst the quality of verbal information initially 
received by consumers varied across practice 
settings, written information was uniformly 
satisfactory and reliant on the use of the ‘little blue 
book’ (Anticoagulant Therapy booklet, Boots 
Pharmaceuticals, manufacturers of CoumadinTM), 
particularly for dietary advice. Consumers depended 
heavily on the booklet, which served both as a 
source of information and as a practical tool for 
managing their therapy (Table 2). Obtaining this 
booklet proved a challenge for some participants 
who, on the advice of their practitioners, tried to 
unsuccessfully obtain the booklet from the 
community pharmacist. For those who were initiated 
on warfarin in the community setting, provision of 
the booklet (when it occurred) was not followed by 
substantial or useful verbal information from the 
community pharmacist. 
Those who commenced therapy in the hospital 
setting and who were counselled by the hospital 
pharmacist were generally satisfied with the verbal 
information received, however that provided by the 
prescribing clinician was variable in content and 
quality. Satisfaction levels were greater when 
information was provided in an atmosphere of 
individualised and focused care, giving consumers 
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the opportunity to process and understand it. A 
personal approach was extremely important in 
terms of ongoing support and the patient’s 
confidence in warfarin therapy (Table 2). 
 
Table 2: Patients experience of information provision 
Regarding written information … 
Each time he goes in he gets the same book.  
 
I have to work with this all the time, every night, put in the reading, put in my dosage. I am juggling it around a bit and it is 
very hard to remember all the things, so I enter it in pencil. I do it as soon as I have left the doctor and as I take them I ink in 
the figure of the dosage and then he also has a record. I don’t have to tell him, I just give it to him and it makes life a lot 
easier. 
 
The specialist didn’t give me this [book] … he said that you could get this book and I had to go to two pharmacists to get 
one …I think it could be better communication … they just gave me the book. 
Regarding education in the hospital… 
The pharmacist came around and explained it all to me in every detail and gave me a book of what I should eat and what I 
shouldn’t eat 
 
There was a team of about five doctors … all around the bed and they all talked to me. 
No criticism of the doctors but not much explanation just a sort of a wry comment, that they use it for rat poison, it was not 
very reassuring. 
 
I didn’t get anything … only very sketchy in [hospital]… I haven’t received anything extra at all  
Regarding education in the community … 
[The chemist] did explain … not to take it with aspirin and things like that … just take it with water. 
 
I go to a big pharmacy in Chatswood and you hand the script over and there are about six pharmacists all rushing around 
like mad things behind the counter … You’ve got about five people lining up to get served … there is a big sign … ‘Talk to 
your pharmacist’ … I don’t know that that is working all that well … there is a need for some sort of central place.  
 
The doctor … looked it up on the computer and he said, “deadly, don’t take any more [tramadol]”… and yet I had asked the 
pharmacist … she said well there is nothing on our computer other than to just watch for any black spots you have come up 
on you … I have got to go back from him and feed her the information that she wasn’t aware of. 
 
I was disappointed that there wasn’t much being done, just a label was just being sent off … I see my GP but he doesn’t 
seem to offer much advice or anything. 
 
Table 3: Patients’ expressed needs for information 
Personally prefer that I read the book first and then come back and say ‘I am not sure about this or that, could you explain 
this to me’ . 
 
I found it very difficult to sit on the other side of [the cardiologist’s] desk and try and make notes of what he was saying. Now 
to him… it is a routine thing that he says  … for me it is the first time I heard this … I don’t think it should be left verbally … 
[and the doctor] follows this up with again verbal advice. 
 
I could have done with a bit more [information] … another microgram or milligram or whatever it is … I just don’t know what 
is too much or too little and I am not clear on INR. I wouldn’t mind knowing a bit about that because I am the one who is 
taking it. That is not a criticism, just a plea for more background. 
 
I did have lots of information, as much as I needed, but when I got home, and practised I found… [that] every two weeks I 
would give blood and it would alter. I just wondered, what is the good of it? …I must have warfarin and they were saying to 
prevent stroke … just want to be sure that I am doing the right thing so I won’t get a stroke. 
 
There is a diabetes educator … who fills me in [on diabetes management] and gives me all the reasoning and good 
motivation to keep at it … I wouldn’t mind there being … a warfarin blood thinning educator … that you could phone or go to 
…because if I’ve got any doubts like that I might stop it entirely. 
 
The local doctor is great for prescribing the next amount to take according to the INR … but I just feel that I am a bit alone, it 
is a bit of a journey travelling solo. Well either the limitations of time to do that or even the limitation of expertise I think … So 
really the scope is something to be set up, educating bureau or forum or something.  
 
There was an expressed need for more information, 
with verbal and written forms of information being 
equally important to patients (Table 3). However, a 
single counselling session and/or the simple supply 
of a booklet was insufficient education for most. 
Some felt that they needed more background 
information about warfarin, such as an explanation 
of the reasons for taking warfarin, how it worked, 
how dose adjustments were made, and observed 
phenomena (e.g., bruising, variable INR results). 
They needed this to solidify their understanding of 
the therapy and therefore their confidence in using 
it, given that it had major impacts on their daily life. 
Neither verbal counselling experiences nor the 
booklet adequately catered to this need. Many 
expressed that the information needed to be 
provided in a paced manner with the opportunity of 
verifying their understanding at a later time. Further, 
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they preferred that it should come from the health 
professionals who were most involved in their care. 
Those who received apparently satisfactory and 
comprehensive education stated that despite this, 
they found it difficult to apply the knowledge once in 
their home setting, particularly when there was no 
reinforcement. The need for ongoing support and 
resources was again paramount for this group of 
consumers. Face-to-face accessible support 
services were necessary. Most felt that the GP was 
not able to offer this sort support, due to time 
restrictions, consequently some consumers felt 
quite solitary in their warfarin management. 
Although few of these consumers had actively 
sought the support and advice of community 
pharmacists regarding warfarin therapy, they were 
generally disheartened about the quality and current 
level services available. They expressed that 
pharmacists did not always have up-to-date 
information, particularly regarding drug interactions. 
Participants were not only dissatisfied by the lack of 
precautionary information about drug interactions 
and adverse effects generally, but also that what 
they did receive from the community pharmacist 
was sometimes retrospective. 
Theme 3: Patients’ reactions to being on warfarin 
Consumers progressed through a ‘cycle of 
reactions’ regarding warfarin use, describing fear, 
followed by acceptance, and then dependence 
(Table 4). Initial fear and anxiety was largely 
directed at the practical aspects of therapy rather 
than any risk of bleeding or adverse events. 
 
Table 4: Consumer reactions to being on warfarin 
On initial reactions  … 
Shock, horror. Yes … when you hear of friends who go onto warfarin … blood testing that is needed to control the warfarin 
properly … that was my first reaction, oh dear oh dear there is another medical procedure which we are forced to follow. It is 
not like taking a Panadol  … certainly you learn to live with it. 
 
My reaction was that I couldn’t eat broccoli and the things I loved, spinach and all those things. 
 
I didn’t have any other sort of reaction. I just accepted it as I had the pacemaker and they told me I was going to be 
wonderful, which was very true … didn’t worry me at all. 
 
I was pleased because this was part of the recovery for me … I have never had any worries about taking it. 
On current attitudes toward warfarin …. 
I’m just not worried about it. Things are going along smoothly and it goes up and down a bit but it doesn’t seem to be 
affecting me, it doesn’t interfere with my life at all. 
 
Happy to take it … if that can avoid the chances of strokes and things … little inconvenience to take it … As far as going to 
pathology on a regular basis, in the early stage it was a big nuisance but you get to know all the girls down at the pathology 
and … (laughter) it was an enjoyable visit every time… I walk around with a smile on my face. 
 
I didn’t care less, it is just another tablet to take. The only thing that annoys me a bit … warfarin doesn’t stop the fibrillation 
as far as I am concerned.  
 
I didn’t take it for six weeks …[then] I had a stroke … I’ve been on it ever since. I wouldn’t have a clue if the INR [blood test 
result] was up or down … doesn’t worry me ... just change the dosage. 
Concerns about day-to-day issues … 
It is all this nonsense, in the garden. Doctor says wear long sleeved shirt and I get too hot to wear a long sleeved shirt so I 
just cope with the black spots that come up and the bleeding … I just put the hose on it and just go ahead.  
 
I often wonder if you did have a fall and the ambulance came and you were bleeding what extra measures the ambulance 
would take … obviously if you are on [warfarin] the bleeding will be a bit harder to stop.  
 
I get a little bit upset when I ring the doctor and … [the blood] is a bit thick at the moment … now what am I not eating, or 
eating or drinking and not drinking that could better the situation … it would be help if I could get some info. 
  
They just say that there may be a reaction to antibiotics, you know just watch out for it, but it is very hard to watch out for 
something when you don’t know whether it is going to cause this or that or the other thing. 
 
Warfarin-naive consumers were less fearful than 
those who had been exposed to stories or myths 
about its use. Following appropriate education, fear 
quickly turned into acceptance of the therapy, 
particularly if warfarin was commenced after a 
significant clinical event or intervention. After a 
period of time in which participants were able to 
establish a routine and get accustomed to the 
therapy, they became somewhat dependent on it. 
They were generally quite accepting of the therapy, 
in spite of the fact that some participants (who were 
misguided about its indication) considered it to be 
ineffective. Those who had previously suffered a 
stroke were dependent on it, whilst those who were 
taking it for primary prevention were more sceptical 
about its use.  
Whilst the majority accepted the doctor’s decision 
and complied with the therapy, not everyone was 
entirely enthusiastic about warfarin; one participant 
in particular was fairly antagonistic towards it, albeit 
for reasons other than the risks of warfarin, and 
constantly raised arguments against its use whilst in 
desperate search of security and reassurance 
regarding it. 
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I am very, very anti-warfarin … it is not the 
warfarin, but you cannot take [naproxen] … I 
suffer from rheumatoid arthritis and you 
cannot take warfarin in conjunction … sotalol 
… it doesn’t have side effects … it has got no 
‘no-nos’. With warfarin … you can’t have other 
things with it, whereas sotalol you can … I am 
terrified of it. 
In terms of ongoing concerns, day-to-day issues 
were more important to participants than monitoring 
issues or adverse effects. Most participants were 
curious rather than fearful about what might happen 
if a serious bleed occurred. Those who reported 
episodes of bleeding regarded them to be no more 
than a ‘nuisance’.   
Many expressed that it was difficult to maintain a 
stable INR and this was reflected in frequent dose 
changing. Although INR fluctuations occurred 
frequently, were annoying and often unexplainable, 
most participants appeared to accept subsequent 
dose changes as a matter of course. All had a good 
recollection of these dose changes. Some 
consumers were bothered by the inability to account 
for the altering INR readings, in spite of their best 
efforts to follow the ‘protocol’ and to watch dietary 
intake of their ‘greens’. Insecurity about dietary 
issues and the concomitant use of other 
medications persisted even after extended periods 
of treatment. 
Theme 4: Self-management of warfarin therapy 
Although most participants were quite happy to 
hand over the management of concomitant 
medication to an external party or carer, they were 
very much in complete control of their warfarin 
(Table 5). Many attached a special significance to it, 
developing routines or systems that essentially 
provided them with a coping strategy for this. What 
the routine entailed was not important, as each 
participant described their own individualised 
method, but rather that it was an intimately 
understood process that empowered them to 
confidently manage their warfarin. 
 
Table 5: Management of warfarin 
On managing warfarin versus other medications … 
Carer: “She takes seven different pills every morning but one day a week she takes an extra one. Now I couldn’t tell you 
what they are all for … I have a very efficient pharmacist and she keeps the prescriptions … gives me a list of what we need 
… we have a little pillbox with all the days on it and every Wednesday I take that up and she fills it up”. 
 
Yet, on warfarin: - 
 
“Actually I am a rather routine person … about all these things and warfarin … I have made out a program”. 
 
Patient: “Yes. [ramipril] and [metoprolol]. I have been taking [them] before warfarin … [ramipril], yes, … what is that for? 
Fibrillation. I don’t know. I really don’t know what I am taking it for. Except the warfarin.”  
 
This same consumer on her warfarin: -  
 
“It is interesting to go back into the old [record book]. I was on 7.5mgs for a long, long time … the last three times I have 
been 2.5 and I have been taking 3.5 so it is a bit different …if I get a virus or infection it always starts off my asthma and 
then of course I am on the antibiotics and the prednisone and then my INR goes up and down”. 
 
On self-developed management strategies ….  
I take mine at 7 o’clock every night. I find that is convenient. We live in the hostel and dinner at night is 6 o’clock, so 7 
o’clock is a good time when I come back and before I sit down at the TV. 
 
I take mine going to bed which is normally 10.30 or 11 o’clock … you get into a pattern and you don’t forget.  
 
On blood-testing routines …. 
I go to a pathology service in Chatswood  …  [the doctor] gets the result… I ring him the next day and say what is the INR 
and then we discuss what I should be doing. 
 
I just go to the local doctor … takes the blood himself and sends it up to pathology … I ring him back at 5 o’clock and he 
says stay as you are or change it around. I have no problem taking it, it is just a routine. 
 
We started off having blood taken once a week, that went on from the start until 9th August, then …went on for some time 
fortnightly. Then it seemed to steady and we have been having it every four weeks … it kept very nicely between 2 and 3 
from the 6th September until the 9th January, it edged up a little like 2.3, 2.8, 2.6, 2.8 and then it got to 3.1 … So after the 3.1 
in the next four weeks it dropped to 2 and so, the pathologist calls and I ring the doctor the next day and they tell me what it 
is. 
 
We tripped around a bit but wherever I was if I was due for an INR I would go to the local pathologist with a letter I was 
given by my doctor …I would get the reading from them and if it was consistent … I just continued on the same dosage… 
That worked all right. 
 
All participants were able to describe exactly how 
they incorporated set routines into their daily lives to 
manage their warfarin and their rationale for this 
regimen. Likewise, each participant had an 
established routine for their blood testing. 
Maintaining a good relationship with the doctor and 
pathology service was important to participants for 
their ongoing monitoring. For this reason, some 
were happy to sacrifice their holidays, or organise 
them around INR tests, so as to not interfere with 
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their well-established and satisfactory testing 
processes. Others were undeterred by this 
prospect. 
Theme 5: Spectrum of experiences with warfarin 
Participants generally reported few problems with 
warfarin use (Table 6). Some consumers reported 
serious episodes of bleeding and considered them 
to be nothing more than annoyances and 
detrimental only in terms of cosmetic effects. A few 
were more concerned that they weren’t bleeding as 
much as anticipated.  
Overall, this consumer group felt that they had little 
to suggest in the way of strategies to assist warfarin 
use and prevent bleeding, given their satisfactory 
management and few adverse experiences. Several 
suggested placing an emphasis on mechanisms 
that alerted others to the fact that they were on 
warfarin, as in the case of emergencies. 
 
Table 6: Spectrum of experiences with warfarin 
On bleeding episodes … 
I have been taking it for five years and I just don’t have any [problems], other than I bleed more freely, I have no reaction to 
it at all. Except for that I wouldn’t know I was taking it. 
 
One day you’re going on perfect and the next day, [bruises] all over me, not from bumping or anything. 
Easy bruising yes. It is very ugly, but you know, just put up with it. 
 
Oh, my wife finds blood all over my clothes when I am out in the garden but still that’s the only inconvenience and 
sometimes you have got to rush in and get a Band-Aid whereas normally you would put up with it and let it bleed but other 
than that, not a problem. 
 
What does it mean when it doesn’t bleed at all? You have a cut and hardly a little line of blood where the cut is … I have 
been waiting for this avalanche of blood. 
On other adverse effects 
Sometimes I get a bit clammy, but it may not be the warfarin it could be other things like the [aspirin]. 
 
I have also got nausea. That might be … I can’t blame warfarin for it … I have fruit juice in the morning and I blame that … 
but I cut it out but I still got nausea. But that’s not fair for warfarin. 
On suggestions to minimise risks of warfarin therapy … 
Get yourself a bracelet … “I take anticoagulants” … a little more stress could be put on the wearing of these things. Whether 
people like it or not … from an ambulance person’s point of view or a doctor’s, it is handy to know this because if you are 
unconscious.  
 
I carry a letter in my handbag wherever I go, my full history and what medications I am on. 
 
DISCUSSION 
Although previous studies have explored the 
perspectives of prescribers18-20, none have probed 
further to identify the experiences and perceptions 
of elderly patients and their carers regarding 
warfarin therapy, despite the reluctance of clinicians 
to prescribe warfarin for elderly patients due to 
perceived patient refusal.7-10 This is the first known 
study to have examined in-depth the perspectives of 
elderly patients and/or their carers in this local 
clinical setting.  
Overall, the results of this study refute the notion 
that elderly patients are likely to refuse warfarin 
therapy. Although its use was an emotive clinical 
process for these participants, the initial fear and 
anxiety was quickly transformed into acceptance, 
and then dependence, following appropriate 
education and an adjustment period (i.e., time to 
establish a management plan and routine). Those 
who were commenced on warfarin after a significant 
clinical event or intervention (biological factor) were 
most accepting of the therapy. A fear of excessive 
bleeding was not expressed as a deterrent to its 
use. Even in those who had experienced some 
bleeding, minor episodes were perceived to be 
more of a cosmetic nuisance, whilst more serious 
bleeds were simply accepted as part of the therapy. 
Of course, these findings pertain to patients who 
have been able to continue warfarin therapy for a 
period of time (i.e., demonstrated tolerability), and 
who had not yet experienced a major adverse 
clinical event requiring therapy to be stopped. 
Regarding the practicalities of the therapy, for the 
most part patients were not deterred by the 
processed involved. Although keeping track of blood 
testing, dosage adjustments, and ‘dietary 
restrictions’ was cumbersome they did not regard 
these to be major impositions upon them. Despite 
clinicians’ concerns about patients’ ability to cope 
with these aspects of warfarin, participants in this 
study did not feel incapable of managing their 
therapy. In fact, they appeared to do so more 
effectively than for other concomitant medication, 
treating warfarin differently and with more respect 
than other medication. Special emphasis was 
placed on warfarin and, in acknowledgement of the 
regimen’s complexity, participants relied on self-
developed routines and independent coping-
mechanisms to assist them. This contrasts with 
health professionals’ perceptions of non-compliance 
with warfarin in the elderly.7-10  
What concerned participants most about warfarin 
therapy was the lack of detailed information to 
support them in the processes (dietary changes, 
blood testing) that they were required to follow 
whilst using warfarin, e.g., accurate information 
about dietary restrictions, the interpretation of blood 
test results. Undertaking these activities was 
physically not a problem, however the lack of 
understanding as to why these things were 
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necessary, and to what extent, created some 
uncertainties and lead them to seek reassurance: 
participants expressed a need for reassurance from 
all of those involved in their treatment, particularly 
the general practitioner. Unequivocally, the general 
practitioner was central to both the practical and 
emotional components of warfarin management, 
and therefore the avoidance of problems associated 
with its use. It was expressed that the difficulties 
with warfarin came from the limited accessibility of 
both the treating general practitioner and other 
services for ongoing support, advice, education, and 
reassurance. For this reason, they felt somewhat 
abandoned in their management of warfarin, and 
were left with no option other than to assume a 
great deal of personal responsibility for their 
therapy. Self-developed strategies for their 
independent management of warfarin were 
therefore necessary.  
The level of attention paid to warfarin is somewhat 
surprising, given that several of the participants did 
not fully understand its purpose. This is important in 
view of previous research that has identified that 
patients are more likely to be non-compliant with 
warfarin when they do not know why it has been 
prescribed, and/or perceive fewer benefits for an 
increased burden.21 Indeed, in this current study, 
those who were most accepting of warfarin were 
those who understood and appreciated its clinical 
importance. Patient knowledge underpins patient 
preferences, and is integral to treatment 
compliance, and this is particularly important for 
decision-making regarding anticoagulant therapy. 
Other studies highlight this, reporting that patient-
perceived thresholds of benefit for choosing 
anticoagulation vary widely and do not always 
coincide with those in clinician-generated 
guidelines, in accordance with the amount of 
information imparted to them.11,12,22  
Overall, these findings are consistent with other 
surveys suggesting that patients’ decision-making is 
primarily driven by the fear of stroke and death, and 
less so by the inconvenience, minor side effects and 
costs of warfarin.22 In terms of the bio-psycho-social 
factors, in the elderly the focus appears to be on the 
psychological factors affecting warfarin use 
(uncertainty regarding the purpose of the therapy, 
the meaning of blood test results, fear of making 
errors in management due to lack of information), 
rather than the biological (physical processes of 
blood testing, episodes of bleeding) or social factors 
(lifestyle changes, limitations to daily activities). This 
is contrary to clinicians’ current perceptions, and 
highlights that patients are quite amenable to the 
therapy, despite any residual anxiety being driven 
by a lack of knowledge. Other studies examining 
biopsychosocial influences on regimen adherence, 
for example in type 1 diabetes, have also shown 
that psychosocial factors, such as education and 
positive coping styles, account for more variance in 
clinical outcomes (e.g., glycaemic control) than 
biological factors.23 
Collectively, what all of these findings highlight is 
the importance of education in helping patients 
appreciate that the benefits of warfarin outweigh the 
costs (risk of bleed, stringent care, monitoring), 
which then influence the acceptability of, 
preferences for, and compliance with therapy. 
Previous studies have also identified that insufficient 
information is provided to patients about therapeutic 
options, particularly elderly patients commenced on 
long-term therapy for chronic conditions such as 
heart disease, asthma, diabetes, arthritis, and 
stroke.24 This prevents their active involvement in 
the therapy and/or participation in decision-making 
processes.25 The results of this study support that 
patients who are armed with knowledge, are more 
accommodating of the therapy in the long-run than 
those who have a limited understanding of the risk 
and benefit of the therapy and/or the additional 
processes involved. Knowledge about the risks and 
benefits of therapy may be partly acquired through 
experiencing the outcome (e.g., stroke), however, 
for a preventative therapy acquisition of knowledge 
in this manner is both inappropriate and ineffective. 
Patients may also acquire information via ill-
informed third parties (e.g., peers and relatives)26, 
and the dangers of relying on this is highlighted by 
the fact that warfarin-naive participants in this study 
were less fearful than those who had been exposed 
to stories or myths about its use. There is an 
identified need for health care professionals to offer 
more education to these patients; the current 
reliance of health carers on the communication of 
information via the provision of a single ‘information 
booklet’ and/or isolated verbal counselling sessions 
is insufficient. This “lack of systematic and 
continuous education” has also been identified for 
young patients with chronic illness.27 It should be 
recognised that, across all age groups, “people’s 
appetite for information about their treatment is 
often greater than doctors believe”.26-28 Greater 
effort is needed to not only educate patients about 
the risks and benefits of treatment, but also to 
provide ongoing services that incorporate follow-up 
care, access to information, and the necessary 
reassurance for patients over the long-term. Such 
an ongoing service should also allow for the 
exchange of information between health 
professionals and patients, including feedback from 
patients to prescribers about their treatment 
preferences.29 Studies are currently underway to 
develop and evaluate appropriate educational 
material for the target elderly population, as well as 
community-based services that incorporate the 
education and counselling of warfarinised patients. 
Although hospital-based anticoagulation clinics are 
a mainstay of care in many countries, their 
accessibility to older patients is somewhat restricted 
(i.e., functional impairments may impede travel to 
clinics), hence the need to develop local, 
community-based services that may outreach to at-
risk older patients. 
In interpreting the findings of this study it is 
important to acknowledge that the perspectives 
raised here by the participants may not necessarily 
be generalisable to all warfarinised patients. Indeed, 
these participants represent patients requiring long-
term therapy who have had (on average) a few 
years to adapt to their treatment regimen and 
therefore may have been more positive in their 
appraisal of warfarin. Additionally, because 
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participation was voluntary, our sample may 
represent those who had particular viewpoints that 
they wished to express, whether positive or 
negative (e.g., grievances). However, careful 
facilitation of the group discussions yielded a 
diverse range of perspectives, both positive and 
negative, as described in the results. Due to the 
restricted sample size and the small number of 
carers, it was not possible to fully elucidate any 
specific differences in perspectives between 
patients and carers, although as a whole, the 
perspectives of both patient/carer groups were 
essentially similar. 
 
CONCLUSIONS 
Elderly patients and their carers appear to be quite 
accepting of warfarin therapy, in contrast to the 
perceptions of health care professionals. More effort 
is needed, however, in terms of information 
provision, particularly in the form of community-
based services, to assist patients in the long-term 
management of warfarin.  
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